Ensuring Safe Handling, GMP Compliance & Cost-Effectiveness of Highly Potent & Cytotoxic Drugs Manufacturing
From Process Safety to Rapid Scale-Up to Tech Transfer: Integrating Process Development, Industrial Hygiene & Equipment Selection to Achieve GMP Manufacturing of
Novel High Potent Drug Compounds
The wave of novel, cytotoxic modalities securing early success and approvals is cementing the growth of highly potent drugs market to reach USD$40.7bn by 2023.
Pressure is mounting on biotechs, pharma, CDMOs, and equipment providers to evolve industrial hygiene, process engineering and manufacturing capabilities to ensure safe handling and effective scale-up to achieve commercial GMP manufacturing.
The 13th HPAPI: Process Development for Highly Potent Drugs Summit united the industry to evaluate efficient high potent compounds synthesis, adoption of innovative technology platforms and occupational safety best practice.
This was your flagship summit, enduring for 13+ years to expedite clinical and commercial manufacturing of novel highly potent drugs. You could have taken advantage of 3-days of end-to-end content catering to all internal stakeholders and explored novel technologies, optimized process development, mitigated cross-contamination and implemented bullet-proof risk assessment of occupational exposure.
You could have joined 130+ experts across CMC, Process Engineering, Industrial Hygiene Leaders from Merck, Gilead, Eli Lilly in June and supercharged cost-effective, GMP compliant scale-up of cytotoxic, highly potent drugs with safety in mind!
Ready to Chat?
Are you ready to talk about your participation in this next year's 14th HPAPI: Process Development for Highly Potent Drugs?
Schedule a call with Silmara who will guide you through the registration process and answer any of your burning questions about the event.
We are keen to hear how you can be a part of our community, and how this meeting can help elevate your practices next year.
Our Process Development for High Potent Drugs
Community Members 2024
Proud to have Partnered with:
